Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 14/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8105526 | 0.91 | MGLL (0.58) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL4500344 | 0.85 | HTR2A (0.56) | MGLLMEN1KMT2ALMNAHSD11B1 | |
| SCHEMBL27892705 | 0.84 | KMT2A (0.65) | MGLLMEN1KMT2ALMNAHSD11B1 | |
| SCHEMBL4509082 | 0.84 | HSD11B1 (0.65) | MGLLHSD11B1 | |
| SCHEMBL13657578 | 0.81 | MGLL (0.71) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL28975834 | 0.81 | POLB (0.57) | MGLLMEN1KMT2AHSD11B1 | |
| (4-Chlorophenyl)(Cyclopropyl)Methanone SCHEMBL392801 | 0.80 | MGLL (0.68) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL14154609 | 0.80 | MGLL (0.69) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL3391998 | 0.80 | MGLL (0.69) | MGLLMEN1KMT2ALMNATP53 | |
| SCHEMBL10638259 | 0.79 | MGLL (0.45) | MGLLMEN1KMT2AHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670379-B2 | Inflammatory or allergic conditions, asthma, inhibition of eosinophil activation, conjunctivitis; (1-((R2-Amino-3-pyridin-3-yl-propyl)-piperidin-4-yl)-(4-fluoro-phenyl) -methanone | NOVARTIS AG (CH) | 2003-12-30 | — | — | US | disclosed |
| US-20030176460-A1 | Piperidine compounds for use as ccr-3 inhibitors | NOVARTIS AG (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-1303488-A1 | PIPERIDINE COMPOUNDS FOR USE AS CCR-3 INHIBITORS | Novartis AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002004420-A1 | PIPERIDINE COUMPOUNDS FOR USE AS CCR-3 INHIBITORS | NOVARTIS AG (CH) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176460-A1 | Piperidine compounds for use as ccr-3 inhibitors | CCR1, CCR3, CCR4 | MGLL 4087/4885MEN1 4248/4885KMT2A 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.